Research To Practice | Oncology Videos

Latest Episodes:

Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma (Companion Faculty Lecture) Sep 28, 2023

Show notes

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics:

Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30)
Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22)
Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54)

CME information and select publications

Ovarian Cancer | Oncology Today with Dr Neil Love: Novel Agents and Strategies in the Treatment of Ovarian Cancer Sep 26, 2023

Show notes

Featuring an interview with Dr Debra Richardson, including the following topics:

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors (0:00)
Activity, safety and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced ovarian cancer (5:12)
ASCO and SGO guidance on the nationwide shortages of carboplatin and cisplatin (9:21)
Investigating mechanisms of resistance to PARP inhibitors; potential use of circulating tumor DNA as an investigational tool (14:13)

CME information and select publications

Ovarian Cancer | Oncology Today with Dr Neil Love: Novel Agents and Strategies in the Treatment of Ovarian Cancer (Companion Faculty Lecture) Sep 26, 2023

Show notes

Featuring a slide presentation and related discussion from Dr Debra Richardson, including the following topics:

Targeting folate receptor alpha in ovarian cancer; activity, tolerability and ongoing investigation of the antibody-drug conjugate (ADC) mirvetuximab soravtansine (0:00)
Other ADCs under investigation for patients with ovarian cancer (20:05)
Mechanism of action and activity of upifitamab rilsodotin (UpRi) for patients with pretreated ovarian cancer (23:27)
Emerging strategies for patients with platinum-resistant ovarian cancer (29:53)
Rationale for the discontinuation of clinical development of UpRi (33:17)

CME information and select publications

Hematologic Oncology | What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors Sep 22, 2023

Show notes

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda, including the following topics:

Introduction: Mentoring Fellows (0:00)
Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction followed by venetoclax/rituximab consolidation in a clinical trial — Spencer Henick Bachow, MD (11:47)
Case: A man in his late 70s with relapsed del(11q) CLL develops atrial fibrillation while receiving ibrutinib — Warren S Brenner, MD (18:15)
Case: A man in his early 70s with CLL develops rash and bruising while receiving ibrutinib — Gigi Chen, MD (27:02)
Case: A man in his late 80s with CLL receives acalabrutinib as initial therapy and experiences thrombocytopenia — Kapisthalam (KS) Kumar, MD (31:42)
Case: A woman in her mid 80s with relapsed CLL (TP53 mutation) discontinues ibrutinib due to bruising — Dr Brenner (40:08)
Case: A man in his early 80s with R/R mantle cell lymphoma discontinues ibrutinib due to bleeding risks after a traumatic head injury — Dr Bachow (49:01)
Case: A man in his late 50s with CLL and response to acalabrutinib develops worsening myalgias a year later — Eric H Lee, MD, PhD (58:36)

CME information and select publications

Pancreatic Cancer | Zev Wainberg, MD, MSc Sep 18, 2023

Show notes

Inside the Issue: Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 1: Selection and Sequencing of Therapy for Metastatic Pancreatic Cancer

CME information and select publications

Pancreatic Cancer | Eileen M O'Reilly, MD Sep 18, 2023

Show notes

Optimizing the Management of Metastatic Pancreatic Cancer | Faculty Presentation 2: Current and Future Role of Biomarker-Based Decision-Making for Metastatic Pancreatic Cancer

CME information and select publications

Pancreatic Cancer | Inside the Issue: Optimizing the Management of Metastatic Pancreatic Cancer Sep 18, 2023

Show notes

Featuring perspectives from Dr Eileen O'Reilly and Dr Zev Wainberg, including the following topics:

Introduction (0:00)
Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Cancer (11:42)
Ongoing Clinical Trials (31:33)
Current and Future Role of Biomarker-Based Decision-Making in Metastatic Pancreatic Cancer (41:04)

CME information and select publications

Non-Hodgkin Lymphoma | Martin Hutchings, MD, PhD Sep 14, 2023

Show notes

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD

CME information and select publications

Non-Hodgkin Lymphoma | Loretta J Nastoupil, MD Sep 14, 2023

Show notes

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD

CME information and select publications

Non-Hodgkin Lymphoma | Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma Sep 14, 2023

Show notes

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil, including the following topics: